D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 94 Citations 44,949 577 World Ranking 4947 National Ranking 147

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Chemotherapy

Mario Boccadoro mostly deals with Multiple myeloma, Surgery, Internal medicine, Bortezomib and Transplantation. His studies deal with areas such as Autologous transplantation and Chemotherapy as well as Multiple myeloma. His studies in Surgery integrate themes in fields like Thalidomide, Dexamethasone and Hazard ratio.

His Internal medicine research integrates issues from Gastroenterology and Oncology. Mario Boccadoro interconnects Proteasome inhibitor, Urology, Survival rate and Adverse effect, Pharmacology in the investigation of issues within Bortezomib. In his study, which falls under the umbrella issue of Transplantation, Risk factor is strongly linked to Survival analysis.

His most cited work include:

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (484 citations)
  • Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial (364 citations)
  • Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial (279 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Oncology, Surgery and Transplantation. In most of his Internal medicine studies, his work intersects topics such as Gastroenterology. His research in Multiple myeloma tackles topics such as Bone marrow which are related to areas like Cancer research.

His research in Oncology intersects with topics in Hematology, Clinical trial, Carfilzomib and Daratumumab. His Lenalidomide study combines topics in areas such as Maintenance therapy and Autologous stem-cell transplantation. The Thalidomide study combines topics in areas such as Adverse effect, Pharmacology and Salvage therapy.

He most often published in these fields:

  • Internal medicine (63.28%)
  • Multiple myeloma (58.55%)
  • Oncology (29.90%)

What were the highlights of his more recent work (between 2018-2021)?

  • Multiple myeloma (58.55%)
  • Internal medicine (63.28%)
  • Oncology (29.90%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Newly diagnosed and Clinical trial. His work carried out in the field of Multiple myeloma brings together such families of science as Intensive care medicine, Maintenance therapy, Transplantation and Minimal residual disease. Lenalidomide, Dexamethasone, Carfilzomib, Bortezomib and Hematology are the core of his Internal medicine study.

His Bortezomib study integrates concerns from other disciplines, such as Thalidomide and Melphalan. The concepts of his Oncology study are interwoven with issues in Ixazomib, Relapsed refractory, Randomized controlled trial and Pomalidomide. In his study, Toxicity is strongly linked to Gastroenterology, which falls under the umbrella field of Newly diagnosed.

Between 2018 and 2021, his most popular works were:

  • Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. (85 citations)
  • Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study (58 citations)
  • Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. (48 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Clinical trial are his primary areas of study. His Multiple myeloma research is multidisciplinary, incorporating elements of Intensive care medicine and Minimal residual disease. His study in Oncology is interdisciplinary in nature, drawing from both Cell therapy and MRD Negativity.

His biological study spans a wide range of topics, including Treatment goals, Chimeric antigen receptor, Progression-free survival and Bone marrow. Mario Boccadoro focuses mostly in the field of Bortezomib, narrowing it down to matters related to Transplantation and, in some cases, Polypharmacy and Watchful waiting. Mario Boccadoro works mostly in the field of Hazard ratio, limiting it down to topics relating to Regimen and, in certain cases, Thalidomide, Phases of clinical research and Intention-to-treat analysis, as a part of the same area of interest.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Leukemia (2010)

749 Citations

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo;Sara Bringhen;Davide Rossi;Maide Cavalli.
Journal of Clinical Oncology (2010)

560 Citations

Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos.
Blood (2011)

375 Citations

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michele Cavo;Lucia Pantani;Maria Teresa Petrucci;Francesca Patriarca.
Blood (2012)

372 Citations

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

Antonio Palumbo;Sara Bringhen;Maria Teresa Petrucci;Pellegrino Musto.
Blood (2004)

362 Citations

Thalidomide for treatment of multiple myeloma: 10 years later

Antonio Palumbo;Thierry Facon;Pieter Sonneveld;Joan Bladè.
Blood (2008)

354 Citations

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Michele Cavo;S. Vincent Rajkumar;Antonio Palumbo;Philippe Moreau.
Blood (2011)

352 Citations

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

Paul Gerard Richardson;Pieter Sonneveld;Michael Schuster;Edward Stadtmauer.
British Journal of Haematology (2009)

344 Citations

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo;Michele Cavo;Sara Bringhen;Elena Zamagni.
Journal of Clinical Oncology (2011)

337 Citations

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

Marco Ladetto;Gloria Pagliano;Simone Ferrero;Federica Cavallo.
Journal of Clinical Oncology (2010)

320 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Mario Boccadoro

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 200

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 191

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 173

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 172

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 147

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 139

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 131

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 128

Maria-Victoria Mateos

Maria-Victoria Mateos

University of Salamanca

Publications: 113

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 112

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 110

Michele Cavo

Michele Cavo

University of Bologna

Publications: 109

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 108

Jesús F. San Miguel

Jesús F. San Miguel

University of Navarra

Publications: 106

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 105

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 104

Trending Scientists

Martin Haenggi

Martin Haenggi

University of Notre Dame

Philippas Tsigas

Philippas Tsigas

Chalmers University of Technology

Mark B. Gagner

Mark B. Gagner

Siemens (Germany)

Michael Lustig

Michael Lustig

University of California, Berkeley

Ilan Halachmi

Ilan Halachmi

Agricultural Research Organization

Scott A. Armstrong

Scott A. Armstrong

Harvard University

Christopher P. Saint

Christopher P. Saint

University of South Australia

G. Gerken

G. Gerken

Essen University Hospital

John Parnell

John Parnell

University of Aberdeen

Benjamin Burkhard

Benjamin Burkhard

University of Hannover

Forrest M. Hoffman

Forrest M. Hoffman

Oak Ridge National Laboratory

Alf Brodal

Alf Brodal

University of Oslo

Wendy Johnson

Wendy Johnson

University of Edinburgh

Kevin Daniels

Kevin Daniels

University of East Anglia

Rolv T. Lie

Rolv T. Lie

University of Bergen

Xin-Nian Wang

Xin-Nian Wang

Central China Normal University

Something went wrong. Please try again later.